Brief: Cingulate And Indegene Announce Joint Commercialization Agreement For Lead ADHD Candidate CTx-1301
13/03/2023 11:50
March 13 (Reuters) - Cingulate Inc CING.O :
* CINGULATE AND INDEGENE ANNOUNCE JOINT COMMERCIALIZATION
AGREEMENT FOR LEAD ADHD CANDIDATE CTX-1301
Source text for Eikon: ID:nGNX5ZNXXW
Further company coverage: CING.O
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)